NCT06359067View on ClinicalTrials.gov

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Multiple Myeloma
Interventions
OTHER

Treated by bispecific antibodies, teclistamab or elranatamab in usual care

Treated by bispecific antibodies, teclistamab or elranatamab in usual care

OTHER

Not treated by bispecific antibodies in usual care

Not treated by bispecific antibodies in usual care

Trial Locations (1)

75004

Assistance Publique - Hôpitaux de Paris (AP-HP), Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER